唐氏综合征筛查后女性对无创产前DNA检测与染色体微阵列的偏好:一项前瞻性研究
该前瞻性队列研究纳入香港三家公立医院中唐氏综合征筛查高风险(≥1:250)或中风险(1:251-1200)的孕妇,高风险者可选择侵入性检测加染色体微阵列、无创产前DNA检测或拒绝进一步检测,中风险者接受无创产前DNA检测作为二次筛查。主要结局为无创产前DNA检测的接受率:高风险组347例中344例(99.1%)选择进一步检测,其中216例(62.2%)选择无创产前DNA检测;中风险组614例中507例(82.6%)选择无创产前DNA检测。
要点
- 高风险组347例中216例(62.2%)选择无创产前DNA检测而非侵入性检测加染色体微阵列。
- 中风险组614例中507例(82.6%)选择无创产前DNA检测作为二次筛查。
- 颈项透明层≥3.5 mm的34例中7例(21%)选择无创产前DNA检测。
核心结论
- 在报告时间相似且无费用差异的情况下,约60%的高风险孕妇选择无创产前DNA检测而非诊断性检测。
研究设计与样本
- 前瞻性队列研究,纳入香港三家公立医院中高风险(≥1:250)或中风险(1:251-1200)孕妇。
主要发现
- 高风险组347例中344例(99.1%)选择进一步检测,其中216例(62.2%)选择无创产前DNA检测。
- 中风险组614例中507例(82.6%)选择无创产前DNA检测。
- 颈项透明层≥3.5 mm的34例中7例(21%)选择无创产前DNA检测。
关键数值与推荐
- 高风险定义为唐氏综合征风险≥1:250,中风险定义为1:251-1200。
- 咨询告知两种检测报告时间相同、操作相关流产风险为0.1-0.2%且筛查免费。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine preferences for follow-up testing in women screened with high or intermediate risk for Down syndrome in the first or second trimester. DESIGN: Prospective cohort study. SETTING: Three public hospitals in Hong Kong, China. SAMPLE: Women with pregnancies termed as high risk (≥1:250; HR) or intermediate risk (1:251-1200; IR) for Down syndrome. METHODS: Women with pregnancies screened as HR were offered the choices of: (1) an invasive test plus chromosomal microarray (CMA) to obtain more detailed fetal genetic information; (2) non-invasive cell-free prenatal DNA screening (NIPT) to detect trisomies 13, 18 and 21, and to avoid procedure-related miscarriage; and (3) to decline any further testing. Women received standardised counselling informing them that the reporting times were identical, the procedure miscarriage risk was 0.1-0.2% and that there was no charge for screening. Women with IR pregnancies (1:251-1200) were offered NIPT as a secondary screening test. MAIN OUTCOME MEASURES: Uptake rate for NIPT. RESULTS: Three hundred and forty-seven women had pregnancies deemed as HR; 344 (99.1%) women opted for follow-up testing, 216 (62.2%) of whom chose NIPT. Five hundred and seven of 614 women (82.6%) with IR risk chose NIPT. Seven (21%) of 34 women with nuchal translucency ≥3.5 mm opted for NIPT. CONCLUSION: In a setting where reporting times are similar and there is no cost difference between options, approximately 60% of women with pregnancies classed as HR would opt for NIPT, offering simple but limited aneuploidy assessment, over a diagnostic procedure with comprehensive and more detailed assessment. TWEETABLE ABSTRACT: 60% of pregnant Chinese women prefer NIPT over CMA when screened as high risk for Down syndrome.
引用
- Cheng Y, Leung WC, Leung TY, et al. Women's preference for non-invasive prenatal DNA testing versus chromosomal microarray after screening for Down syndrome: a prospective study. BJOG. 2018. PMID: 29125674. doi:10.1111/1471-0528.15022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。